Skip to main content
. 2017 Dec 9;8(69):113895–113909. doi: 10.18632/oncotarget.23040

Figure 2. Differential phosphorylation of pathway proteins after RTX vs. obinutuzumab treatment.

Figure 2

Swissprot human taxonomic protein database identify proteins phosphorylated at serine, threonine and tyrosine residues. Proteins with >1.5 fold increase in phosphorylation between anti-CD20 mAbs (RTX and Obinutuzumab) and IgG treatment in (A) Raji and (B) Raji4RH (P=0.05) were identified in multiple cellular pathways.